


A Severe Asthma Roadmap





Biomarkers

No T2 biomarkers

- Blood eosinophil <150 µL AND
- FeNO < 20 ppb <u>AND</u>
- Sputum or BAL eosinophil < 2%

OR

If sputum BAL neutrophils also < 40-60% = pauciinflammatory

Associated Phenotypes

- Obestiy
- Smoking History
- Infections
- Lack of response to corticosteroids

Treatment

- Secretion clearance

- Pulmonary

rehabilitation

- Weight loss
- Bariatric surgery
- Macrolide antibiotics
- Bronchial Thermoplasty

+ Consider experimental therapy from clinical trials with Anti-TSLP, Anti-IL-6, Anti-IL-17 or other drugs in development.

Biomarkers

Blood eosinophils > 150 μL
FeNO > 20 ppb

Sputum or BAL eosinophils > 2%
Elevated IgE

Associated Phenotypes

- Early age onset
- History of allergies
- Chronic Rhinosinusitis/Nasal Polyps

This reference aid was developed as part of an educational activity supported by independent educational grants from AstraZeneca Pharmaceuticals LP, GlaxoSmithKline and Novartis Pharmaceuticals Corporation.

References

Anti-IgE Omalizumab Allergic Noneosinophilic Asthma Anti-IL-4Ra/13 Dupilumab Eosinophilic Asthma who: Mepolizumab, Anti-IL-5 Are nonallergic **OR** Reslizumab • Do not respond to anti-lgE treatment OR Anti-IL-5Ra Benralizumab Are out of dosing range for anti-IgE treatment Anti-IL-4Ra/13 Dupilumab Anti-IL-4Ra/13 Dupilumab* *While Dupilumab has the FDA indication **OCS** Dependence for OCS dependence, both Mepolizumab and Benralizumab have shown efficacy. **Considerations for Related Type 2 Phenotypes** Atopic Dematitis Anti-IL-4Ra/13 Dupilumab Chronic Idiopathic Urticaria Omalizumab Anti-IgE Chronic Rhinosinusitis and Nasal Polyps Anti-IL-4Ra/13 Dupilumab*

Anti-IL-4Ra/13

Dupilumab

Consider patient preference factors related to route/frequency/location of administration and cost.

Global Initiative for Asthma (GINA) Global Strategy for Asthma Management and Prevention. 2019. www.ginasthma.org US National Heart, Lung, and Blood Institute (NHLBI) National Asthma Education and Prevention Program Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. 2007. www.nhlbi.nih.gov/files/docs/guidelines/asthgdln.pdf Chung KF, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343-7 Israel E, Reddel HK. Severe and difficult-to-treat asthma in adults. N Engl J Med. 2017;377(10):965-976. Wechsler ME. Getting control of uncontrolled asthma. Am J Med. 2014;127(11):1049-59 Bousquet J, et al. Care pathways for the selection of a biologic in severe asthma. Eur Respir J. 2017;50(6). Chipps BE, et al. Asthma Yardstick: Practical recommendations for a sustained step-up in asthma therapy for poorly controlled asthma. Ann Allergy Asthma Immunol. 2017;118(2):133-142 Lefebvre P, et al. Acute and chronic systemic corticosteroid-related complications in patients with severe asthma. J Allergy Clin Immunol. 2015;136(6):1488-1495.